Literature DB >> 7552308

Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat.

C Tassorelli1, S A Joseph.   

Abstract

Nitroglycerin is a vasodilator which induces vascular relaxation by releasing nitric oxide in the wall of blood vessels. It has been suggested that the cardiovascular inhibitory responses which are induced by this drug are mediated by central structures. In this study, we evaluated the distribution and intensity of Fos immunoreactivity in rat brain nuclei following the systemic administration of nitroglycerin. In the medulla, a significant number of Fos-immunoreactive neurons were observed in the nucleus tractus solitarius, ventrolateral medulla, area postrema and spinal trigeminal nucleus caudalis. A robust staining was seen in the parabrachial nucleus, locus coeruleus and ventrolateral periaqueductal grey. In the hypothalamus, Fos-positive cells were densely packed in the paraventricular and supraoptic nuclei. Other areas where significant staining was observed include the central nucleus of the amygdala and the subfornical organ. These findings demonstrate that the systemic administration of nitroglycerin is capable of activating a spectrum of functionally diverse brain regions. This spectrum includes areas involved in reflex adjustments to nitroglycerin-induced hypotension, areas involved in sensory nociceptive perception and areas associated with integrative regulation of autonomic, behavioral and neuroendocrine functions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552308     DOI: 10.1016/0006-8993(95)00348-t

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  56 in total

1.  Pressor response to pulsatile compression of the rostral ventrolateral medulla mediated by nitric oxide and c-fos expression.

Authors:  S Morimoto; S Sasaki; S Miki; T Kawa; H Itoh; T Nakata; K Takeda; M Nakagawa
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 2.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 3.  Diencephalic and brainstem mechanisms in migraine.

Authors:  Simon Akerman; Philip R Holland; Peter J Goadsby
Journal:  Nat Rev Neurosci       Date:  2011-09-20       Impact factor: 34.870

4.  Sodium MRI in a rat migraine model and a NEURON simulation study support a role for sodium in migraine.

Authors:  Michael G Harrington; Eduard Y Chekmenev; Victor Schepkin; Alfred N Fonteh; Xianghong Arakaki
Journal:  Cephalalgia       Date:  2011-08-04       Impact factor: 6.292

Review 5.  Where does a migraine attack originate? In the brainstem.

Authors:  J Tajti; D Szok; Á Párdutz; B Tuka; A Csáti; A Kuris; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

Review 6.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 7.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 8.  [What is needed to develop a headache? Anatomical and pathophysiological implications].

Authors:  U Reuter; A May
Journal:  Schmerz       Date:  2004-10       Impact factor: 1.107

9.  Polymorphism in apolipoprotein E among migraineurs and tension-type headache subjects.

Authors:  Ravi Gupta; Vivek Kumar; Kalpana Luthra; Basudeb Banerjee; Manjeet Singh Bhatia
Journal:  J Headache Pain       Date:  2009-01-31       Impact factor: 7.277

Review 10.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.